What is KORU Medical's gross profit margin?

What is the revenue and EPS growth rate for KORU Medical year over year?

What does KORU Medical do and what are its main business segments?

What factors drove the changes in KORU Medical's revenue and profit?

What guidance did KORU Medical's management provide for the next earnings period?

What is the market's earnings forecast for KORU Medical next quarter?

Did KORU Medical beat or miss consensus estimates last quarter?

What were the key takeaways from KORU Medical's earnings call?

- **CEO Transition**: Linda Tharby retiring; Adam Kalbermatten to lead, ensuring strategic continuity.
- **Revenue Growth**: 2025 full-year $41.1M (+22% YoY); 2026 guidance $47.5M-$50M (+15%-22%).
- **Strategic Milestones**: EU MDR certification, RYSTIGGO clearance, 80% international growth.
- **Financial Health**: Positive cash flow, 62.3% gross margin, 2026 EBITDA positivity.
- **Future Opportunities**: Oncology pipeline, Japan expansion, 3M+ annual infusions from new therapies.

**【CEO Summary Section】**
- Linda Tharby announced her retirement as CEO, effective June 30, 2026, with Adam Kalbermatten succeeding her as CEO starting July 1, 2026. Tharby highlighted KORU's 2025 performance, including Q4 revenue of $10.9 million (23% YoY growth) and full-year revenue of $41.1 million (22% YoY growth). Key achievements included EU MDR certification for the Freedom60 pump, RYSTIGGO 510(k) clearance, and 80% international Core growth. 2026 guidance is $47.5 million to $50 million in revenue, with positive adjusted EBITDA and cash flow.

**【CFO Financial Commentary】**
- Q4 2025 GAAP net income was $420 million, with Non-GAAP EPS of $1.08. Full-year gross margin was 62.3%, despite headwinds from material costs and tariffs. Cash flow improved, with $8.9 million ending cash and positive cash flow from operations. 2026 guidance includes 15%-22% revenue growth, 61%-63% gross margin, and positive adjusted EBITDA.

**【Q&A Highlights】**
- **International Expansion**: FREEDOM60 MDR certification enables EU prefilled syringe conversions, targeting $50 million market. 2026 expects 1-2 new EU markets quarterly. 
- **Domestic Growth**: U.S. Core grew 18% YoY, driven by SCIg market share gains. New drug clearances (e.g., RYSTIGGO) and oncology pipeline (ESCO) anticipate 2026 infusions.
- **New Therapies**: Phase III nephrology and Phase I multi-indication drugs add 3 million annual infusions. RYSTIGGO's 2026 U.S. opportunity is 20,000-100,000 infusions.
- **Japan Market**: Pumps and consumables approved; growth tied to prefilled syringe adoption, targeting $0.5-$1 million opportunity.

KORU Medical Systems, Inc.(KRMD)-20260313-2025 Q4 Earnings call transcript

- **Revenue Surge**: Q3 revenue up 27% YoY, driven by 30% SCIg growth and 230% international expansion via European PFS conversions.
- **Oncology Breakthrough**: U.S. pilot study success (100% administration success rate) with 70% nurse multitasking capability; FDA submission expected by end-2025.
- **Guidance Raise**: Full-year revenue guidance raised to $40.5-41 million (20-22% growth), with 61-63% gross margin maintained despite $1.2 million revenue shift.
- **2026 Vision**: CEO signals 20%+ growth potential from oncology, international PFS, and new drug collaborations, targeting 65%+ gross margin over 3-4 years.

**【CEO Summary】**
- **Revenue Growth**: Q3 revenue exceeded $10 million for the second consecutive quarter, up 27% YoY, driven by 30% growth in the core SCIg business. International revenue surged 230% due to prefilled syringe (PFS) conversions in Europe.
- **Pipeline Expansion**: Announced 2 new PST collaborations, expanding into oncology with a U.S. pilot study achieving 100% success rate and nurse satisfaction. Oncology 510(k) submission expected by end of 2025.
- **Guidance Update**: Raised full-year revenue guidance to $40.5-41 million (20-22% growth) and reaffirmed gross margin targets of 61-63%.

**【CFO Financial Commentary】**
- **Revenue Dynamics**: Domestic revenue declined 5% due to a distributor inventory reduction, while international growth offset this with $1.2 million in unexpected revenue from cross-border transactions.
- **Gross Margin**: 60.2% (down 320bps YoY) due to higher manufacturing costs and tariffs. Expect Q4 cost improvements and full-year margin adherence to 61-63% guidance.
- **Cash Flow**: Generated $400,000 in cash flow, ending Q3 with $8.5 million in cash and positive adjusted EBITDA.

**【Q&A Highlights】**
- **Oncology Reimbursement**: Existing codes cover pump-based administration, enabling quick adoption post-FDA approval. 2026 oncology market entry expected.
- **2026 Outlook**: CEO hints at 20%+ growth driven by international PFS expansion, oncology launches, and new drug collaborations. Gross margin target of 65%+ over 3-4 years.
- **Japan Market**: Early-stage sales ($300-500k in 2025) expected to grow slowly, with focus on Europe's faster PFS adoption (targeting 40% market share by 2030).

KORU Medical Systems, Inc. (KRMD) Q3 2025 Earnings Call Transcript

- **Record Revenue Growth**: Q2 2025 revenue of $10.2 million (+21% YoY) driven by 34% international expansion and 42% PST growth.
- **Profitability Progress**: Cash usage down 90% to $600,000 vs. $5.9 million in 2023; on track for positive cash flow in 2025.
- **Guidance Raise**: 2025 revenue updated to $39.5-$40.5 million (+18%-20%), reflecting international prefilled syringe momentum.
- **Strategic Momentum**: FDA approval of Empaveli's expanded indication, Phase I flow controller launch, and Japan market entry.

**【CEO Opening Remarks】**
- Q2 2025 revenue reached $10.2 million, a 21% year-over-year increase, driven by growth across all three strategic pillars: domestic core business, international expansion, and Pharma Services & Clinical Trials (PST).
- Domestic core revenue grew 15% to $7.1 million, outpacing the SCIg market, while international revenue surged 34% to $2.2 million, fueled by prefilled syringe conversions in Europe.
- PST revenue rose 42% to $900,000, driven by clinical trial orders for non-Ig drugs.
- Key milestones include FDA approval of Empaveli's expanded indication, a 510(k) submission for a rare disease biologic, and the launch of the Phase I flow controller.
- The company achieved cash usage of $600,000 in Q2, down from $5.9 million in 2023, with a goal of positive cash flow for the full year.

**【CFO Financial Commentary】**
- Gross margin for Q2 was 63.5%, down 150 basis points year-over-year due to tariffs and prior-year inventory adjustments. Full-year gross margin guidance remains 61%-63%.
- Cash balance ended the quarter at $8.1 million, with cash usage of $600,000, reflecting improved operational efficiency.
- Updated 2025 revenue guidance raised to $39.5-$40.5 million (18%-20% growth), driven by international prefilled syringe conversions offsetting a U.S. distributor inventory reduction.
- Operating expenses exclusive of stock compensation are expected to be $26-$27 million, with R&D spending accelerating in the second half.

**【Q&A Highlights】**
- **International Growth**: Europe's prefilled syringe market conversion is expected to drive 30%+ growth in the back half, with one top-5 European market seeing KORU's share rise to low 20s from 10%-15%. Japan's first sales are anticipated in Q4, with significant 2026 potential.
- **Domestic Dynamics**: U.S. distributor inventory reduction in Q3 will be offset by strong end-user demand, with SCIg market growth expected to remain high single to low double digits.
- **Product Delays**: The next-gen pump submission is on track for Q4 2025/Q1 2026, while consumable set delays will not impact 2025/2026 revenue.
- **Tariff Mitigation**: Operational efficiency initiatives and vendor rebates are reducing tariff impacts, which are expected to stabilize at 2% of orders.
- **Cash Strategy**: Positive cash flow is expected for the full year, with reinvestment focused on growth opportunities like oncology pilots and international expansion.

KORU Medical Systems, Inc. (KRMD) Q2 2025 Earnings Call Transcript

- **Revenue Beat**: Q1 $9.6M (+18% YoY), driven by 36% international growth and 16% U.S. core expansion.
- **Pipeline Acceleration**: 2 new drug submissions to add $0.5M+ in 2026, with <$0.5M investment and 1-year payback.
- **Gross Margin Expansion**: 62.8% (up 50bps YoY), targeting 61%-63% for 2025 despite 100bps tariff headwind.
- **Japan Opportunity**: Full system clearance achieved; distributor stocking to drive $0.5M+ in 2025.
- **Oncology Momentum**: 5 pilot sites validate economic value; full launch in 2026 with 3 pharma partners.

**【CEO Opening Remarks】**
- Q1 2025 revenue reached $9.6 million, up 18% YoY, driven by 16% growth in domestic core business and 36% surge in international markets.
- Launched 2 new commercialized drugs for 510(k) clearance, bringing total pipeline to 5 submissions in 2025.
- Gross margin improved to 62.8% (up 50bps YoY) due to operational efficiencies.
- Raised 2025 revenue guidance to $38.5M-$39.5M (15%-17% growth) and reaffirmed 61%-63% gross margin target.
- International expansion focuses on Japan, Middle East, and EU, targeting 30%-40% market share in key SCIg markets.
- New drug pipeline includes 17 opportunities, with 9 expected to contribute by 2026, including oncology clinic pilots.

**【CFO Financial Highlights】**
- Q1 GAAP net income: $420M; Non-GAAP EPS: $1.08 (exceeds expectations).
- Domestic core: $6.9M (+16% YoY); International: $2.4M (+36% YoY) due to distributor stocking and new market wins.
- Pharma Services/Clinical Trials: $0.3M (-39% YoY) due to delayed clinical trials.
- Cash balance: $8.7M; Cash usage: $0.8M (36% YoY improvement).
- 2025 operating expenses: $26M-$27M; Capital expenditures: <$2M for next-gen production lines.

**【Q&A Key Takeaways】**
- **International Growth**: Japan to contribute $0.5M+ in 2025; 30%+ YoY international expansion driven by prefilled syringe tenders.
- **New Drug Strategy**: 2 new independent submissions (iron chelation, antibiotics) with <$0.5M investment, 1-year payback.
- **Tariff Impact**: 100bps annualized headwind offset by U.S. margin strength and operational excellence.
- **Oncology Clinics**: 5 pilot sites validate workflow efficiency and higher reimbursement rates; full commercial launch in 2026.
- **Supply Chain**: 90%+ raw materials U.S.-sourced; Nicaragua manufacturing costs neutralized by volume growth.
- **Recurrence**: 75% of revenue from chronic SCIg patients (45,000+ patients, 2M+ annual infusions).

KORU Medical Systems (KRMD)-7 May 25-2025 Q1 Earnings call transcript

- **Revenue Growth Acceleration**: 2024 total revenue up 18% to $33.6M, with 2025 guidance of $38-39M (+13-16%).
- **Margin Expansion**: Gross margin improved 480bps to 63.4% in 2024, targeting 61-63% in 2025 with long-term >65% potential.
- **Pipeline Catalysts**: 15 novel therapy collaborations, including 7 with 2026 commercial potential, and 300,000+ annual infusions from a nephrology drug.
- **International Expansion**: OUS revenue grew 32% in 2024, targeting >20% growth in 2025 with Japan market entry and ePump needle set adoption.
- **Operational Efficiency**: Reduced cash burn by 68% to $1.9M in 2024, with plans for positive operational cash flow in 2025.


**【CEO Strategic Overview】**
- **2024 Financial Highlights**: Total revenue reached $33.6 million (+18%), driven by core business (+16%), international expansion (+32%), and novel therapies (+62%).
- **Market Growth & Penetration**: SCIg market grew 10% in 2024, with KORU capturing 10% of the $60M OUS market. 75% of revenue comes from recurring chronic patients (49,000 total patients).
- **2025 Guidance**: Revenue $38-39M (+13-16%), gross margin 61-63%, and positive operational cash flow.
- **Pipeline Momentum**: 15 novel therapy collaborations (4 added in 2024), with 7 potential 2026 launches, including 300,000+ annual infusions from a nephrology drug.

**【CFO Financial Details】**
- **Q4 2024 Results**: Revenue $8.8M (+23%), gross margin 62.9%, and $9.6M cash balance (vs. $8.8M target).
- **Full Year 2024**: Gross margin improved 480bps to 63.4%, cash burn reduced 68% to $1.9M, and non-GAAP EPS exceeded expectations.
- **2025 Financials**: Operating expenses $26-27M, capital spend <$2M, and focus on manufacturing efficiency to maintain margins despite supply chain costs.

**【Q&A Key Takeaways】**
- **Growth Drivers**: Domestic core (+10-15%), international (+>20%), and novel therapies ($2-3M). Japan entry and ePump needle sets drive OUS expansion.
- **Gross Margin Outlook**: Long-term target >65% via new consumables automation and premium pricing for next-gen products.
- **Risks & Challenges**: Tariffs add <0.5% margin pressure, but minimal impact on core components.
- **Clinical Trials**: 5 Phase III collaborations in pipeline, with oncology market research underway for U.S. launch.


Actual	0.0369	0.0179	-0.0178	-0.03	-0.02	-0.02	-0.02	-0.05	-0.06	-0.03	-0.04	-0.05	-0.05	-0.03	-0.02	-0.04	-0.01	-0.03	-0.03	0	0.01	-0.02	-0.01
Forecast	0.02	0.0196	-0.0057	-0.0067	-0.02	-0.0244	-0.0339	-0.0567	-0.0637	-0.0542	-0.0568	-0.05	-0.0567	-0.05	-0.04	-0.038	-0.043	-0.0389	-0.028	-0.03	-0.0225	-0.0244	-0.02
Surprise	+84.50%	-8.67%	-212.28%	-347.76%	0.00%	+18.03%	+41.00%	+11.82%	+5.81%	+44.65%	+29.58%	0.00%	+11.82%	+40.00%	+50.00%	-5.26%	+76.74%	+22.88%	-7.14%	+100.00%	+144.44%	+18.03%	+50.00%

KRMD

KRMD fundamentals

KRMD Q4 2025 Earnings

Earnings Call

You can ask Aime

KRMD

KRMD fundamentals

KRMD Q4 2025 Earnings

Earnings Call

KRMD Earnings Call Summary for Q4/20254:30 PM on Mar 12, 2026

KRMD Earnings Call Summary for Q3/20254:30 PM on Nov 12, 2025

KRMD Earnings Call Summary for Q2/20254:30 PM on Aug 6, 2025

KRMD Earnings Call Summary for Q1/20254:30 PM on May 7, 2025

KRMD Earnings Call Summary for Q4/20244:30 PM on Mar 12, 2025

You can ask Aime